Merck unveils results from Phase 2 trial of V114 vaccine in infants
Category: #health  By Pankaj Singh  Date: 2019-05-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck unveils results from Phase 2 trial of V114 vaccine in infants

V114 has secured a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) to avert invasive pneumococcal disease (IPD) in January 2019.

The U.S. based multinational pharmaceutical company Merck, also known as MSD outside Canada and the United States, has reportedly announced the results from a Phase 2 trial evaluating the immunogenicity, safety, and tolerability of V114. The experimental 15-valent pneumococcal conjugate vaccine of the company, in comparison with the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age.

Reportedly, in the trial, selected V114-008, V114 intersected its primary endpoint for the 13 serotypes contained in both the vaccines by indicating noninferiority. V114 also brought on an immune reaction in newborns for two additional serotypes, 22F and 33F, causing diseases.  These serotypes are not contained in PCV13.

V114 has secured a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) to avert invasive pneumococcal disease (IPD) in January 2019. IPD is triggered in pediatric patients aging from 6 weeks to 18 years by the vaccine serotypes. The decision of FDA was partially informed by immunogenicity data from this Phase 2 study, the Phase 1/2 V114-005 study and V114-008 in healthy adults and infants. The outcomes of the V114-008 study were shown during an oral session at the 37thAnnual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, and strengthen continued progression of Phase 3 clinical studies with V114.

V114-008, a double-blind, randomized, Phase 2 trial, compared the tolerability, immunogenicity, and safety of two distinct clinical lots of V114 (n=350 for lot 1; n=347 for lot 2) to PCV13 (n=347) in around 1,050 healthy infants aging two, four, six and 12-15 months. In the study, the percentage of subjects attaining the upper limit of immune reaction (IgG≥0.35 mcg/mL) accepted by WHO with lot of V114 was noninferior to the percentage observed with PCV13 for the 13 serotypes shared between the two vaccines.

Source credit: https://www.businesswire.com/news/home/20190508005210/en/Merck-Announces-Results-Phase-2-Trial-Investigational

https://www.mrknewsroom.com/news-release/research-and-development-news/merck-announces-results-phase-2-trial-investigational-15-



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...